ANI Pharmaceuticals
ANIP
170 hedge funds and large institutions have $319M invested in ANI Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 52 increasing their positions, 64 reducing their positions, and 22 closing their positions.
40% more call options, than puts
Call options by funds: $1.55M | Put options by funds: $1.11M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 22
2% less funds holding
Funds holding: 173 → 170 (-3)
3.7% less ownership
Funds ownership: 63.45% → 59.76% (-3.7%)
19% less repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 64
25% less capital invested
Capital invested by funds: $424M → $319M (-$105M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICOM
Investment Counselors of Maryland
Baltimore,
Maryland
|
+$9.62M |
| 2 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
+$3.94M |
| 3 |
MCM
Matarin Capital Management
New York
|
+$1.97M |
| 4 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$1.94M |
| 5 |
PFC
Phocas Financial Corp
Alameda,
California
|
+$1.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSV Asset Management
Chicago,
Illinois
|
-$12.1M |
| 2 |
Nomura Holdings
Tokyo,
Japan
|
-$10.8M |
| 3 |
CAM
Cortina Asset Management
Milwaukee,
Wisconsin
|
-$4.14M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$3.13M |
| 5 |
Goldman Sachs
New York
|
-$2.78M |
ANIP Hedge Fund Activity: Q4 2018 in Review
170 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q4 2018, worth a combined $319M — down 25% from $424M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of ANIP and 21 opened new positions — a net loss of 1 holder — while 64 trimmed existing stakes and 52 added.
The largest buyer was Investment Counselors of Maryland, adding an estimated $9.62M. The largest seller was LSV Asset Management, cutting an estimated $12.1M.
- 170 institutional investors held ANI Pharmaceuticals (ANIP) as of Q4 2018, down from 173 in Q3 2018.
- Funds reported $319M of ANI Pharmaceuticals stock for Q4 2018, down 25% quarter-over-quarter.
- 21 funds opened new ANI Pharmaceuticals positions in Q4 2018 and 22 closed out, a net change of -1 holder.
- The largest ANI Pharmaceuticals buyer in Q4 2018 was Investment Counselors of Maryland, an estimated $9.62M added.
- The largest ANI Pharmaceuticals seller in Q4 2018 was LSV Asset Management, an estimated $12.1M sold.
Based on aggregated 13F filings for Q4 2018.